ES2062519T5 - Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t. - Google Patents
Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t.Info
- Publication number
- ES2062519T5 ES2062519T5 ES90905821T ES90905821T ES2062519T5 ES 2062519 T5 ES2062519 T5 ES 2062519T5 ES 90905821 T ES90905821 T ES 90905821T ES 90905821 T ES90905821 T ES 90905821T ES 2062519 T5 ES2062519 T5 ES 2062519T5
- Authority
- ES
- Spain
- Prior art keywords
- cells
- mediate
- pathology
- tcr
- vaccination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001717 pathogenic effect Effects 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title abstract 2
- 210000004698 lymphocyte Anatomy 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 229960005486 vaccine Drugs 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 3
- 230000007170 pathology Effects 0.000 abstract 3
- 230000028993 immune response Effects 0.000 abstract 2
- 230000008506 pathogenesis Effects 0.000 abstract 2
- 201000003068 rheumatic fever Diseases 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCION PROPORCIONA VACUNAS Y UN ELEMENTO DE VACUNACION DE UN MAMIFERO PARA EVITAR O CONTROLAR LAS PATOLOGIAS MEDIADAS POR CELULA T ESPECIFICA O PARA TRATAR LA REPRODUCCION INCONTROLADA DE CELULAS T. LA VACUNA ESTA COMPUESTA DE UN RECEPTOR DE CELULA T (TCR) O UN FRAGMENTO SUYO CORRESPONDIENTE A UN TCR PRESENTE EN LA SUPERFICIE DE CELULAS T QUE MEDIAN LA PATOLOGIA. EL FRAGMENTO DE VACUNA PUEDE SER UN PEPTIDO CORRESPONDIENTE A LAS SECUENCIAS DE TCRS CARACTERISTICA DE LAS CELULAS T QUE MEDIAN ESTA PATOLOGIA. TAMBIEN SE PRESENTAN MEDIOS DE DETERMINACION DE SECUENCIAS DE AMINO-ACIDOS APROPIADAS PARA ESTAS VACUNAS. LA VACUNA SE SE ADMINISTRA AL MAMIFERO DE UNA FORMA QUE INDUCE UNA RESPUESTA INMUNOLOGICA DIRIGIDA CONTRA EL TCR DE CELULAS T QUE MEDIAN LA PATOLOGIA . ESTA RESPUESTA INMUNOLOGICA REGULA HACIA ABAJO O RETRASA LAS CELULAS T PATOGENAS, SOMETIENDO ASI A ABLACION LA PATOGENESIS DE LA ENFERMEDAD. LA INVENCION PROPORCIONA ADICIONALMENTE UNA REGION VARIABLE ESPEFIFICA DE CADENA(BETA) DEL RECEPTOR DE CELULA T, LLAMADO V(BETA)17, QUE ES CENTRAL A LA PATOGENESIS DE ARTRITIS REUMATICA (RA). TAMBIEN SE PRESENTAN MEDIOS PARA DETECTAR, PREVENIR Y TRATAR RA
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32631489A | 1989-03-21 | 1989-03-21 | |
US38208589A | 1989-07-18 | 1989-07-18 | |
US38208689A | 1989-07-18 | 1989-07-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
ES2062519T3 ES2062519T3 (es) | 1994-12-16 |
ES2062519T5 true ES2062519T5 (es) | 2003-07-16 |
Family
ID=27406453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES90905821T Expired - Lifetime ES2062519T5 (es) | 1989-03-21 | 1990-03-21 | Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t. |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0463101B2 (es) |
JP (1) | JP3472297B2 (es) |
KR (1) | KR920700674A (es) |
AU (5) | AU6892994A (es) |
BG (1) | BG61164B1 (es) |
CA (1) | CA2046909A1 (es) |
DE (1) | DE69006018T3 (es) |
DK (1) | DK0463101T3 (es) |
ES (1) | ES2062519T5 (es) |
FI (1) | FI914432A0 (es) |
NO (2) | NO309164B1 (es) |
RO (1) | RO110397B1 (es) |
RU (1) | RU2138512C1 (es) |
WO (1) | WO1990011294A1 (es) |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6221352B1 (en) | 1989-03-21 | 2001-04-24 | The Immune Response Corporation | Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells |
US5612035A (en) * | 1989-03-21 | 1997-03-18 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
US6207645B1 (en) * | 1989-03-21 | 2001-03-27 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations |
US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
US5298396A (en) * | 1989-11-15 | 1994-03-29 | National Jewish Center For Immunology And Respiratory Medicine | Method for identifying T cells disease involved in autoimmune disease |
CA2101065A1 (en) * | 1991-01-22 | 1992-07-23 | Mark D. Howell | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
CA2110055C (en) * | 1991-05-31 | 2002-08-20 | Arthur A. Vandenbark | T cell receptor peptides as therapeutics for immune-related disease |
WO1993004695A1 (en) * | 1991-08-28 | 1993-03-18 | The Wistar Institute | T cell receptor-based therapy for rheumatoid arthritis |
WO1993006135A1 (en) * | 1991-09-23 | 1993-04-01 | Genentech, Inc. | Diagnosing and treating autoimmune disorders |
CA2126686A1 (en) * | 1991-12-24 | 1993-07-08 | Mark D. Howell | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations |
AU4529793A (en) * | 1992-06-08 | 1994-01-04 | Colorado State University Research Foundation | Endogenous ligands for cdr4 of t-cell receptor beta -chains and genes encoding the same |
IL108926A0 (en) * | 1993-05-14 | 1994-06-24 | L Willems Instituut Dr | Human t cell monoclone, process for its production and its use for the treatment and diagnosis of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer |
US5552300A (en) * | 1994-01-13 | 1996-09-03 | T Cell Sciences, Inc. | T cell antigen receptor V region proteins and methods of preparation thereof |
US6034064A (en) * | 1995-04-07 | 2000-03-07 | Hoechst Pharmaceuticals & Chemicals K.K. | Peptides and therapeutic agent for autoimmune diseases containing the same |
EP1299128A2 (en) | 2000-06-20 | 2003-04-09 | Idec Pharmaceuticals Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
WO2002060484A1 (en) | 2001-01-31 | 2002-08-08 | Idec Pharmaceuticals Corporation | Use of cd23 antagonists for the treatment of neoplastic disorders |
US20020159996A1 (en) | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
ES2322267T3 (es) | 2003-04-09 | 2009-06-18 | Genentech, Inc. | Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa. |
KR20070029733A (ko) | 2004-06-04 | 2007-03-14 | 제넨테크, 인크. | 다발성 경화증의 치료 방법 |
CN105535967B (zh) | 2005-02-15 | 2022-05-03 | 杜克大学 | 抗cd19抗体及其在肿瘤学中的应用 |
CA2597325A1 (en) | 2005-03-10 | 2006-09-21 | Genentech, Inc. | Methods and compositions for modulating vascular integrity |
AU2006244445B2 (en) | 2005-05-05 | 2013-04-18 | Duke University | Anti-CD19 antibody therapy for autoimmune disease |
EP2540741A1 (en) | 2006-03-06 | 2013-01-02 | Aeres Biomedical Limited | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
JP5575636B2 (ja) | 2007-05-07 | 2014-08-20 | メディミューン,エルエルシー | 抗icos抗体ならびに、腫瘍、移植および自己免疫疾患の治療におけるその使用 |
EP2200611A4 (en) | 2007-09-14 | 2010-09-22 | Biogen Idec Inc | COMPOSITIONS AND METHODS FOR TREATING PROGRESSIVE MULTIFOCAL LEUCOENCEPHALEPATHY (PML) |
WO2009070642A1 (en) | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
EP2113560A1 (en) * | 2008-04-28 | 2009-11-04 | TXCell | Compositions for treating an arthritic condition |
PL2279004T3 (pl) | 2008-05-16 | 2015-06-30 | Hoffmann La Roche | Zastosowanie biomarkerów do oceny leczenia zaburzeń zapalnych przewodu pokarmowego antagonistami integryny beta7 |
AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
EP2379585A2 (en) | 2008-10-10 | 2011-10-26 | Anaphore, Inc. | Polypeptides that bind trail-ri and trail-r2 |
CA2743469C (en) | 2008-11-12 | 2019-01-15 | Medimmune, Llc | Antibody formulation |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
NZ597531A (en) | 2009-07-31 | 2014-05-30 | Genentech Inc | Inhibition of tumor metastasis using bv8- or g-csf-antagonists |
NZ598962A (en) | 2009-09-16 | 2014-12-24 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
WO2011033006A1 (en) | 2009-09-17 | 2011-03-24 | F. Hoffmann-La Roche Ag | Methods and compositions for diagnostics use in cancer patients |
WO2011060015A1 (en) | 2009-11-11 | 2011-05-19 | Genentech, Inc. | Methods and compositions for detecting target proteins |
JP6184695B2 (ja) | 2009-12-04 | 2017-08-23 | ジェネンテック, インコーポレイテッド | 多重特異性抗体、抗体アナログ、組成物、及び方法 |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
TWI586806B (zh) | 2010-04-23 | 2017-06-11 | 建南德克公司 | 異多聚體蛋白質之製造 |
CA2807278A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann - La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
CN103476793A (zh) | 2010-11-08 | 2013-12-25 | 基因技术公司 | 皮下施用的抗-il-6受体抗体 |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
EP2670776B1 (en) | 2011-02-04 | 2018-11-21 | F. Hoffmann-La Roche AG | Fc VARIANTS AND METHODS FOR THEIR PRODUCTION |
US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
BR112013023787A2 (pt) | 2011-03-31 | 2017-06-13 | Genentech Inc | método de tratamento de um distúrbio inflamatório gastrointestinal em um paciente, artigo de manufatura e método para induzir a remissão prolongada em um paciente sofrendo de colite ulcerativa |
WO2013013708A1 (en) | 2011-07-26 | 2013-01-31 | Fundació Institut D'investigació Biomèdica De Bellvitge | Treatment of acute rejection in renal transplant |
KR20140068877A (ko) | 2011-08-17 | 2014-06-09 | 제넨테크, 인크. | 불응성 종양에서의 혈관신생의 억제 |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
WO2013101771A2 (en) | 2011-12-30 | 2013-07-04 | Genentech, Inc. | Compositions and method for treating autoimmune diseases |
KR20140119777A (ko) | 2012-01-31 | 2014-10-10 | 제넨테크, 인크. | 항-ig-e m1'' 항체 및 그의 사용 방법 |
WO2013119966A2 (en) | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
KR20140123571A (ko) | 2012-02-16 | 2014-10-22 | 에이티와이알 파마, 인코포레이티드 | 자가면역 및 염증성 질환의 치료를 위한 히스티딜trna 신테타제 |
BR112014028368A2 (pt) | 2012-06-27 | 2017-11-14 | Hoffmann La Roche | método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica |
EP2867253B1 (en) | 2012-06-27 | 2016-09-14 | F. Hoffmann-La Roche AG | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
PL2903691T3 (pl) | 2012-10-05 | 2019-10-31 | Hoffmann La Roche | Sposoby diagnozowania i leczenia nieswoistego zapalenia jelit |
CA2901126C (en) | 2013-02-25 | 2022-01-25 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
US9682071B2 (en) | 2013-03-15 | 2017-06-20 | Intermune, Inc. | Methods of improving microvascular integrity |
JP6615745B2 (ja) | 2013-03-27 | 2019-12-04 | ジェネンテック, インコーポレイテッド | ベータ7インテグリンアンタゴニストによる胃腸炎症障害の治療を評価するためのバイオマーカーの使用 |
SG11201607938UA (en) | 2014-03-27 | 2016-10-28 | Genentech Inc | Methods for diagnosing and treating inflammatory bowel disease |
BR112016024462B1 (pt) | 2014-05-06 | 2022-12-27 | Genentech, Inc | Métodos para a preparação de um anticorpo |
EP3191520B1 (en) | 2014-09-12 | 2020-01-01 | Genentech, Inc. | Anti-cll-1 antibodies and immunoconjugates |
WO2016087416A1 (en) | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
EP3227336B1 (en) | 2014-12-05 | 2019-07-03 | F.Hoffmann-La Roche Ag | Anti-cd79b antibodies and methods of use |
JP2018507868A (ja) | 2015-02-26 | 2018-03-22 | ジェネンテック, インコーポレイテッド | インテグリンベータ7アンタゴニスト及びクローン病の治療方法 |
TW201718647A (zh) | 2015-06-16 | 2017-06-01 | 建南德克公司 | 抗-cll-1抗體及使用方法 |
LT3313879T (lt) | 2015-06-24 | 2022-03-25 | F. Hoffmann-La Roche Ag | Antikūnai prieš transferino receptorių su pritaikytu giminingumu |
JP2018520153A (ja) | 2015-06-29 | 2018-07-26 | ジェネンテック, インコーポレイテッド | 臓器移植における使用のためのii型抗cd20抗体 |
TWI819458B (zh) | 2015-10-02 | 2023-10-21 | 瑞士商赫孚孟拉羅股份公司 | 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法 |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
JP2018529747A (ja) | 2015-10-06 | 2018-10-11 | ジェネンテック, インコーポレイテッド | 多発性硬化症を治療するための方法 |
KR20180098625A (ko) | 2015-12-30 | 2018-09-04 | 제넨테크, 인크. | 분해가 감소된 폴리소르베이트를 갖는 제형 |
JP2019522633A (ja) | 2016-05-20 | 2019-08-15 | ジェネンテック, インコーポレイテッド | Protac抗体コンジュゲート及び使用方法 |
EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018112235A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor |
WO2018112255A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
WO2018112223A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
CN117045784A (zh) | 2016-12-14 | 2023-11-14 | 比奥拉治疗股份有限公司 | 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病 |
WO2018112237A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor |
KR102616436B1 (ko) | 2016-12-14 | 2023-12-27 | 비오라 쎄라퓨틱스, 인크. | Tnf 저해제로의 위장관 질환의 치료 |
EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
EP4190318A1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a jak inhibitor and devices |
EP3600249A1 (en) | 2017-03-30 | 2020-02-05 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor |
WO2018183932A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor |
WO2018183931A1 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist |
WO2018183941A2 (en) | 2017-03-30 | 2018-10-04 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with live biotherapeutics |
CN117338932A (zh) | 2017-08-23 | 2024-01-05 | 科智生命科学公司 | 自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂 |
RU2698048C2 (ru) | 2017-10-03 | 2019-08-21 | Закрытое Акционерное Общество "Биокад" | МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα |
US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
AU2019278927A1 (en) | 2018-06-01 | 2020-12-24 | Biora Therapeutics, Inc. | Devices and systems for gastrointestinal microbiome detection and manipulation |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
JP2022505450A (ja) | 2018-10-24 | 2022-01-14 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | コンジュゲート化された化学的分解誘導物質および使用方法 |
RU2724469C2 (ru) | 2018-10-31 | 2020-06-23 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с cd20 |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
EP3884276A2 (en) | 2018-11-23 | 2021-09-29 | Katholieke Universiteit Leuven | Predicting a treatment response in inflammatory bowel disease |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
AU2019428629A1 (en) | 2019-02-06 | 2021-01-28 | Sangamo Therapeutics, Inc. | Method for the treatment of mucopolysaccharidosis type I |
MX2021012152A (es) | 2019-04-02 | 2021-11-03 | Sangamo Therapeutics Inc | Metodos para el tratamiento de beta-talasemia. |
CN115666704A (zh) | 2019-12-13 | 2023-01-31 | 比奥拉治疗股份有限公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
TW202330613A (zh) | 2021-11-12 | 2023-08-01 | 美商建南德克公司 | 使用整聯蛋白β7拮抗劑治療克隆氏病之方法 |
WO2024127332A1 (en) | 2022-12-14 | 2024-06-20 | Pheon Therapeutics Ltd | Cytotoxic compounds |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4886743A (en) * | 1985-04-24 | 1989-12-12 | California Institute Of Technology | Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof |
EP0248887B1 (en) * | 1985-12-03 | 1994-12-28 | T Cell Sciences, Inc. | Cell-free t cell antigen receptor and its clinical utilities |
FI891226A (fi) * | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
-
1990
- 1990-03-21 WO PCT/US1990/001516 patent/WO1990011294A1/en active IP Right Grant
- 1990-03-21 DK DK90905821.6T patent/DK0463101T3/da active
- 1990-03-21 ES ES90905821T patent/ES2062519T5/es not_active Expired - Lifetime
- 1990-03-21 RO RO92-200175A patent/RO110397B1/ro unknown
- 1990-03-21 RU SU5001756A patent/RU2138512C1/ru active
- 1990-03-21 CA CA002046909A patent/CA2046909A1/en not_active Abandoned
- 1990-03-21 DE DE69006018T patent/DE69006018T3/de not_active Expired - Fee Related
- 1990-03-21 JP JP50552090A patent/JP3472297B2/ja not_active Expired - Fee Related
- 1990-03-21 KR KR1019910701170A patent/KR920700674A/ko not_active Application Discontinuation
- 1990-03-21 EP EP90905821A patent/EP0463101B2/en not_active Expired - Lifetime
-
1991
- 1991-09-20 NO NO913722A patent/NO309164B1/no unknown
- 1991-09-20 FI FI914432A patent/FI914432A0/fi unknown
- 1991-10-17 BG BG95337A patent/BG61164B1/bg unknown
-
1994
- 1994-08-05 AU AU68929/94A patent/AU6892994A/en not_active Abandoned
- 1994-08-05 AU AU68928/94A patent/AU6892894A/en not_active Abandoned
- 1994-08-05 AU AU68926/94A patent/AU672313B2/en not_active Ceased
- 1994-08-05 AU AU68930/94A patent/AU6893094A/en not_active Abandoned
-
1996
- 1996-12-24 AU AU76500/96A patent/AU7650096A/en not_active Abandoned
-
2000
- 2000-05-10 NO NO20002425A patent/NO20002425D0/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR920700674A (ko) | 1992-08-10 |
AU7650096A (en) | 1997-02-13 |
FI914432A0 (fi) | 1991-09-20 |
RU2138512C1 (ru) | 1999-09-27 |
AU6892994A (en) | 1994-10-27 |
NO20002425L (no) | 1991-09-20 |
AU648753B2 (en) | 1994-05-05 |
AU6893094A (en) | 1994-11-24 |
ES2062519T3 (es) | 1994-12-16 |
JPH04506512A (ja) | 1992-11-12 |
NO309164B1 (no) | 2000-12-18 |
AU6892694A (en) | 1994-10-27 |
DE69006018T3 (de) | 2004-01-15 |
AU6892894A (en) | 1994-11-03 |
WO1990011294A1 (en) | 1990-10-04 |
NO913722D0 (no) | 1991-09-20 |
EP0463101B2 (en) | 2003-03-19 |
JP3472297B2 (ja) | 2003-12-02 |
EP0463101A1 (en) | 1992-01-02 |
NO913722L (no) | 1991-09-20 |
AU672313B2 (en) | 1996-09-26 |
CA2046909A1 (en) | 1990-09-22 |
DE69006018T2 (de) | 1994-05-11 |
RO110397B1 (ro) | 1996-01-30 |
AU5356790A (en) | 1990-10-22 |
BG61164B1 (bg) | 1997-01-31 |
DE69006018D1 (de) | 1994-02-24 |
BG95337A (bg) | 1993-12-24 |
EP0463101B1 (en) | 1994-01-12 |
DK0463101T3 (da) | 1994-03-14 |
NO20002425D0 (no) | 2000-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2062519T5 (es) | Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t. | |
Scott | IL-12: initiation cytokine for cell-mediated immunity | |
Okumura et al. | Specific enrichment of the suppressor T cell bearing IJ determinants: parallel functional and serological characterizations. | |
Riggs | Recent advances in cryptosporidiosis: the immune response | |
Doolan et al. | IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model | |
Requena et al. | Evolutionarily conserved proteins as prominent immunogens during Leishmania infections | |
Hartmann et al. | Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo | |
Kojima et al. | Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine | |
Courret et al. | Presentation of the Leishmania antigen LACK by infected macrophages is dependent upon the virulence of the phagocytosed parasites | |
Black et al. | Prospects for vaccination against pathogenic African trypanosomes | |
Terrazas et al. | Th1-type cytokines improve resistance to murine cysticercosis caused by Taenia crassiceps | |
Yoshida et al. | Arabinofuranosyl-terminated and mannosylated lipoarabinomannans from Mycobacterium tuberculosis induce different levels of interleukin-12 expression in murine macrophages | |
AU5538900A (en) | Immunostimulant oligonucleotide | |
WO1992012996A3 (en) | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations | |
Reed et al. | Development of a leishmaniasis vaccine: the importance of MPL | |
Vincent et al. | Lyme arthritis synovial γδ T cells respond to Borrelia burgdorferi lipoproteins and lipidated hexapeptides | |
Grainger et al. | Contextual functions of antigen‐presenting cells in the gastrointestinal tract | |
Park et al. | Primary induction of CD4 T cell responses in nasal associated lymphoid tissue during group A streptococcal infection | |
Reiner et al. | Cytokines in the differentiation of Th1/Th2 CD4+ subsets in leishmaniasis | |
WO1993012814A3 (en) | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations | |
Morita et al. | Direct presentation of non-peptide prenyl pyrophosphate antigens to human γδ T cells | |
EP1492814B1 (fr) | Peptide dérivé de l'interleukine-1-beta et son application thérapeutique | |
Morales et al. | Cryptosporidium parvum-specific CD4 Th1 cells from sensitized donors responding to both fractionated and recombinant antigenic proteins | |
Pereira et al. | Humoral and cellular immune responses in BALB/c and C57BL/6 mice immunized with cytoplasmic (CRA) and flagellar (FRA) recombinant repetitive antigens, in acute experimental Trypanosoma cruzi infection | |
Okada et al. | LPS-or 8Br-Cyclic AMP-Induced Production of T Cell-Activating Factor (s) in Macrophage Tumor Cell Line J774. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 463101 Country of ref document: ES |